Related Experiment Video

Updated: Jun 7, 2025

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

65.2K

Targeting the cholinergic anti-inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study

Joseph Magagnoli1,2, Tammy H Cummings1,2, James W Hardin1,3

  • 1Dorn Research Institute, Columbia VA Health Care System, Columbia, South Carolina, USA.

Diabetes, Obesity & Metabolism
|November 12, 2024
PubMed
Abstract

Insights

Galantamine use may lower type 2 diabetes mellitus risk in early-onset Alzheimer's disease patients. This suggests potential new therapeutic avenues for preventing T2DM in this population.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Endocrinology

Background:

  • Chronic inflammation is a key driver in type 2 diabetes mellitus (T2DM) development.
  • The cholinergic anti-inflammatory pathway (CAP) modulates inflammation via α7 nicotinic acetylcholine receptors (α7nAChRs).
  • Acetylcholinesterase inhibitors (AChEis), used for Alzheimer's disease (AD), may possess anti-inflammatory properties.

Purpose of the Study:

  • To investigate the association between AChEi use, specifically galantamine, and the risk of developing T2DM in patients with AD.
  • To explore potential anti-inflammatory mechanisms of galantamine in the context of T2DM prevention.

Main Methods:

  • Retrospective analysis of Veterans Health Administration (VA) data.
  • Inclusion of early- and late-onset AD patients treated with galantamine or other AD medications.
  • Propensity score matching and Cox proportional hazard models to assess T2DM risk.

Main Results:

  • Galantamine use was linked to a significantly reduced T2DM risk in early-onset AD patients (HR=0.80, CI: 0.66-0.98).
  • Memantine also showed a protective effect against T2DM in the early-onset AD group (HR=0.82, CI: 0.69-1).
  • No significant association between galantamine, memantine, or other AD medications and T2DM risk was observed in late-onset AD patients.

Conclusions:

  • Galantamine use is associated with a lower risk of T2DM in early-onset AD patients, possibly via enhanced anti-inflammatory effects.
  • Memantine also demonstrated a protective effect in this specific patient subgroup.
  • Findings suggest potential repurposing of AD medications for T2DM prevention, warranting further investigation in diverse populations.
Keywords:
database researcheffectivenesspharmacoepidemiologytype 2 diabetes

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.8K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
159
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172